At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Quetiapine fumarate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD
In Brief
A Phase 3 clinical trial evaluating Quetiapine fumarate and Duloxetine for Major Depressive Disorder. Completed, across 34 sites.
Detailed Summary
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedMay 2006
Study CompletionMay 2007
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartApr 1, 2006
Study CompletionMay 1, 2007
TodayJul 2, 2026
Posted 20.2 years ago
Interventions
Quetiapine fumaratedrug
Duloxetinedrug